TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8245325

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg once daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Coumadin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Aspirin (in lesions with < 90% stenosis)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Coumadin (in lesions with < 90% stenosis)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (in lesions with < 90% stenosis)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Aspirin (in complex lesions)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Coumadin (in complex lesions)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (in complex lesions)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Stenosis severity > 90%
Number of subjects: 300
Study: 3510650

Group type: EXPERIMENTAL
Intervention: Egg and cow's milk exclusion diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study: 31592825

Group type: COMPARATOR
Intervention: Monotherapy with 50 s.U ABO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with ≤1 mL HA filler
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with ≤50 s.U ABO, ≤2 mL HA filler, and ≤1 mL RSB
Number of subjects: 0
Study: 31747862

Group type: EXPERIMENTAL
Intervention: rs12143842 (in the NOS1AP locus)
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 2282
Study: 27282797

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 24970885

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1200 mg/d
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (RAS inhibitors only)
Number of subjects: 169
Study: 23652031

Group type: EXPERIMENTAL
Intervention: Progesterone cream (80 mg applied daily for 14 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Progesterone gel (80 mg applied daily for 14 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Progesterone cream
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Progesterone gel
Number of subjects: 10
Study: 21291441

Group type: EXPERIMENTAL
Intervention: ParentCorps (13 group sessions for parents and children facilitated by teachers and mental health professionals)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ParentCorps
Number of subjects: 171
Study: 19850347

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 764
Study: 17094038

Group type: EXPERIMENTAL
Intervention: Antenatal treatment with intravenous gammaglobulin (IVIG) and/or corticosteroids
Number of subjects: 71
Study: 15277417

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11298254

Group type: EXPERIMENTAL
Intervention: Medication information leaflets in addition to verbal information
Number of subjects: 54

Group type: COMPARATOR
Intervention: Verbal medication information by nurse or psychiatrist (Control)
Number of subjects: 54
Study: 9404207

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7937786

Group type: EXPERIMENTAL
Intervention: Administration of the advanced glycation inhibitor aminoguanidine to diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: AGE-modified LDL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native LDL incubated with synthetic AGE-peptides
Number of subjects: 0
Study: 2908716

Group type: EXPERIMENTAL
Intervention: Trimazosin 50 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trimazosin 100 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trimazosin 200 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31519517

Group type: EXPERIMENTAL
Intervention: Escitalopram + Memantine (ESC/MEM)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Escitalopram + Placebo (ESC/PBO)
Number of subjects: 95
Study: 29285613

Group type: EXPERIMENTAL
Intervention: Risk adapted damage control orthopedics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard orthopedic treatment (implied control)
Number of subjects: 0
Study: 28109313

Group type: EXPERIMENTAL
Intervention: Informed Healthcare Choices podcast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical public service announcements about health issues
Number of subjects: 0
Study: 25686680

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study: 23639861

Group type: EXPERIMENTAL
Intervention: Bowman Birk Inhibitor (BBI) complex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21624036

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU) treatment during pregnancy
Number of subjects: 2830

Group type: EXPERIMENTAL
Intervention: Methimazole/carbimazole (MMI) treatment during pregnancy
Number of subjects: 2830

Group type: COMPARATOR
Intervention: No antithyroid treatment during pregnancy
Number of subjects: 2830
Study: 18573692

Group type: EXPERIMENTAL
Intervention: Home care (HC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 31
Study: 16584345

Group type: EXPERIMENTAL
Intervention: Bone graft (BG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bone graft plus a bioabsorbable collagen membrane (BG + C)
Number of subjects: 27
Study: 15043176

Group type: EXPERIMENTAL
Intervention: Educational videotape (20-minute)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no videotape)
Number of subjects: 160
Study: 10767063

Group type: EXPERIMENTAL
Intervention: 3D spiral sequence
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2D spiral sequence
Number of subjects: 15
Study: 8807647

Group type: EXPERIMENTAL
Intervention: Standardized rigid contact lens fitting protocol
Number of subjects: 30
Study: 1402218

Group type: EXPERIMENTAL
Intervention: labetalol (200 mg t.t.d.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: acebutolol (200 mg t.t.d.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: metoprolol (100 mg t.t.d.)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 6359885

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31234665

Group type: EXPERIMENTAL
Intervention: Abbreviated schedule with three injections at weekly intervals
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cluster schedule with two administrations in 1 day
Number of subjects: 47
Study: 29540213

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including algorithm-driven antihypertensive treatment using single-pill combination (SPC), motivational conversation, telephone-based follow-ups, and discounts on SPC antihypertensive medications.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care (control group) provided in four polyclinics.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1000
Study: 27107025

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) using Japanese cedar (JC) pollen extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24867693

Group type: EXPERIMENTAL
Intervention: Resistance training (INT), thrice weekly sessions of four exercises, 3‐4 sets/exercise of 10‐15 repetitions at 12‐15 repetition maximum load
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Healthy age‐matched subjects (REF)
Number of subjects: 30
Study: 19586136

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 36
Study: 16390397

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) chemoprophylaxis, daily for 1 year
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no INH)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) chemoprophylaxis
Number of subjects: 109
Study: 11173138

Group type: EXPERIMENTAL
Intervention: bcl-2 positive patients
Number of subjects: 400

Group type: COMPARATOR
Intervention: bcl-2 negative patients
Number of subjects: 400
Study: 9705020

Group type: EXPERIMENTAL
Intervention: Obesity (BMI >= 30 kg/m2)
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: Hypertension (HT)
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia (HC)
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemia (HTG)
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: Elevated LDL
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: Low HDL
Number of subjects: 2836
Study: 7805428

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin twice daily for 9 days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin twice daily for 9 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 76
Study: 3383985

Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal 5‐phosphate glutamate (MPPG) 3 x 50 mg for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study: 12057715

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral micronized estradiol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both interventions (Transdermal and Oral)
Number of subjects: 11
Study: 29871891

Group type: EXPERIMENTAL
Intervention: Therapist BI
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Computer BI
Number of subjects: 836

Group type: COMPARATOR
Intervention: Post-ED BIs
Number of subjects: 836
Study: 26840915

Group type: EXPERIMENTAL
Intervention: Fresh blood transfusions (mean age 4.0 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-issue blood transfusions (mean age 23.2 days)
Number of subjects: 20
Study: 25099545

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein infusion (hydrolyzed whey) 30 kcal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein infusion (hydrolyzed whey) 90 kcal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein infusion (hydrolyzed whey) 180 kcal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (saline infusion, 0 kcal)
Number of subjects: 20
Study: 22267334

Group type: EXPERIMENTAL
Intervention: Conventional immunosuppressive (IS) treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy individuals (Control)
Number of subjects: 17
Study: 20384751

Group type: EXPERIMENTAL
Intervention: Topical bimatoprost 0.03% applied to the upper lid margin once daily for 12 weeks
Number of subjects: 28
Study: 18520801

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m on day 1 and Vinorelbine (VNR) 20 mg/m on days 1 and 8 every 4 weeks with concurrent thoracic radiotherapy (TRT) of 60 Gy in 30 fractions.
Number of subjects: 73
Study: 16297773

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 97
Study: 12028321

Group type: EXPERIMENTAL
Intervention: Frovatriptan (oral administration)
Number of subjects: 0
Study: 10496576

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5-day hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham treatment (21% oxygen for 1 hour per day at 1.2 atm)
Number of subjects: 66
Study: 8739162

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (Corsodyl)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine (Eludril)
Number of subjects: 19
Study: 1768031

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 50
Study: 7066163

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study: 31985248

Group type: EXPERIMENTAL
Intervention: Functional analysis-guided modular intervention (FAMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (manualized intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (manualized intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study: 30610210

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 30
Study: 30235726

Group type: EXPERIMENTAL
Intervention: Yikou-Sizi powder hot compress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27496126

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive training for 30 min over 35 sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 23408278

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 667
Study: 22295883

Group type: EXPERIMENTAL
Intervention: Statin therapy initiated within 72 hours of hospitalization
Number of subjects: 8052

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 8052
Study: 20815975

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18160008

Group type: EXPERIMENTAL
Intervention: LPV/r 800/200 mg QD
Number of subjects: 190

Group type: COMPARATOR
Intervention: LPV/r 400/100 mg BID
Number of subjects: 190
Study: 16317266

Group type: EXPERIMENTAL
Intervention: Erlotinib (50-100 mg/d) with concurrent gemcitabine (75 mg/m2) and paclitaxel (40 mg/m) for 6 weeks, followed by maintenance erlotinib (150 mg/d) until disease progression.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Erlotinib (50 mg/d) with chemoradiation.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib (150 mg/d).
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Erlotinib dosages > or =75 mg/d with chemoradiation.
Number of subjects: 17
Study: 12423841

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen plus micronized progesterone cyclical
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875

Group type: COMPARATOR
Intervention: Conjugated equine estrogen
Number of subjects: 875

Group type: COMPARATOR
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate continuous
Number of subjects: 875

Group type: COMPARATOR
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate cyclical
Number of subjects: 875
Study: 9598705

Group type: EXPERIMENTAL
Intervention: Moderate drinking among men
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Baseline pattern of drinking eight or more drinks per occasion, but less than once a month among men
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5887
Study: 7694913

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2702966

Group type: EXPERIMENTAL
Intervention: Adenosine (maximum tolerated dose: 10.3 +/- 2.3 mg)
Number of subjects: 5
Study: 792851

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 31289092

Group type: EXPERIMENTAL
Intervention: 4 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 L split‐dose PEG‐ELS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 L split‐dose PEG‐ELS
Number of subjects: 0
Study: 28408544

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 36
Study: 25937255

Group type: EXPERIMENTAL
Intervention: Shenfu decoction (SFD)
Number of subjects: 40
Study: 23678857

Group type: EXPERIMENTAL
Intervention: PVI followed by LA linear and CFAE ablation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PVI followed by LA linear, CFAE, and CTI ablations
Number of subjects: 210

Group type: COMPARATOR
Intervention: PVI and CFAE ablation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Follow-up after final ablation procedure
Number of subjects: 210
Study: 21736777

Group type: EXPERIMENTAL
Intervention: Low-GI meals
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High-GL meals
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High-GI meals
Number of subjects: 74
Study: 20014258

Group type: EXPERIMENTAL
Intervention: 1,064 nm Nd:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1,320 nm laser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1,064/1,320 nm multiplex laser system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tumescent liposculpture
Number of subjects: 20
Study: 16567381

Group type: COMPARATOR
Intervention: Ad libitum high-carbohydrate diet (18% fat, 19% protein, 63% carbohydrate)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ad libitum high-carbohydrate diet plus aerobic exercise training (4 d/wk, 45 min/d, 80% VO(2peak)) for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ad libitum high-carbohydrate diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ad libitum high-carbohydrate diet plus aerobic exercise training
Number of subjects: 22
Study: 12946073

Group type: EXPERIMENTAL
Intervention: AMSA injection using the Wand with 1.8 mL of 2% lidocaine solution with 1/80,000 epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control side (no AMSA injection)
Number of subjects: 20
Study: 10769922

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture group
Number of subjects: 0
Study: 9160032

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative mitomycin 0.2 mg/ml four times a day x 7 days (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin 0.4 mg/ml x 3 minutes (group 3)
Number of subjects: 50
Study: 8430051

Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) MPH
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Slow Release (SR) MPH
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Slow Release chewed (CH) MPH
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) MPH
Number of subjects: 11
Study: 3027604

Group type: EXPERIMENTAL
Intervention: Methoxamine (3.5-7 micrograms/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methoxamine with thymoxamine (strong alpha-1-adrenergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine (1-12 micrograms/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prenalterol (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (250 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yohimbine (effective dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine at high infusion rates
Number of subjects: 0
Study: 31300288

Group type: EXPERIMENTAL
Intervention: 23vPPV
Number of subjects: 215

Group type: COMPARATOR
Intervention: PCV7 + 23vPPV
Number of subjects: 215
Study: 28028194

Group type: EXPERIMENTAL
Intervention: Probenecid (500-1000 mg/d)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Allopurinol (300-600 mg/d)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 27909139

Group type: EXPERIMENTAL
Intervention: SBI-087 (200 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 24828019

Group type: EXPERIMENTAL
Intervention: Folate-5: 5 mg/day folate supplements
Number of subjects: 81

Group type: COMPARATOR
Intervention: Folate-1: 1 mg/day folate supplements
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 21751197

Group type: EXPERIMENTAL
Intervention: 15 mg/m² clofarabine daily × 5 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 30 mg/m² clofarabine daily × 5 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both doses of clofarabine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 30 mg/m² clofarabine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 15 mg/m² clofarabine
Number of subjects: 58
Study: 19464029

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (surgery group; n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Expectant management (control group; n = 20)
Number of subjects: 39
Study: 17764554

Group type: EXPERIMENTAL
Intervention: LCS AP glide prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rotating platform prosthesis
Number of subjects: 0
Study: 15333398

Group type: EXPERIMENTAL
Intervention: Opioid-related symptom distress scale (SDS) questionnaire
Number of subjects: 193
Study: 11070749

Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 45